KRAS and neoplasm: The advancement in targeted data-independent acquisition (DIA) analysis for detecting different RAS mutations from FFPE tumor samples [19] and achieving quantitative target engagement analysis of KRASG12C with its inhibitor (AZD4625) in the FFPE xenograft model proved that MS is an indispensable tool not only for KRAS testing from FFPE samples but also for measuring drug response from FFPE samples that cannot be analyzed by DNA-sequencing-based methods [20].